Published in Public Health Genomics on February 20, 2009
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Translational research in cancer genetics: the road less traveled. Public Health Genomics (2009) 1.65
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Barriers to the use of personalized medicine in breast cancer. J Oncol Pract (2012) 1.15
Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev (2011) 1.13
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet (2013) 0.96
Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res (2009) 0.95
Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting. J Cancer Epidemiol (2012) 0.93
Capturing the clinical utility of genomic testing: medical recommendations following pediatric microarray. Eur J Hum Genet (2014) 0.78
Rethinking our public health genetics research paradigm. Am J Public Health (2013) 0.78
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA (2003) 14.72
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
The concept of access: definition and relationship to consumer satisfaction. Med Care (1981) 10.22
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
Distrust, race, and research. Arch Intern Med (2002) 9.67
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med (2007) 9.48
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Financial anatomy of biomedical research. JAMA (2005) 7.49
Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol (2002) 5.81
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA (2005) 4.93
Research funding. NIH in the post-doubling era: realities and strategies. Science (2006) 4.72
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Educating health-care professionals about genetics and genomics. Nat Rev Genet (2007) 4.04
Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health (2006) 3.25
Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol (2002) 3.23
Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin Pharmacol Ther (2007) 3.04
Cost of cancer care: issues and implications. J Clin Oncol (2007) 3.00
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol (2006) 2.92
Racial differences in trust in health care providers. Arch Intern Med (2006) 2.80
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev (1999) 2.52
Health information systems - past, present, future. Int J Med Inform (2005) 2.28
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol (2007) 2.09
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
Translation in the health professions: converting science into action. Eval Health Prof (2006) 1.93
A national framework for cancer surveillance in the United States. Cancer Causes Control (2005) 1.89
Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. Ann Epidemiol (2000) 1.79
Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol (2006) 1.60
Cost of cancer care: the patient perspective. J Clin Oncol (2007) 1.55
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53
Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol (2005) 1.53
Education in a genomic world. J Med Philos (2002) 1.52
Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med (2005) 1.48
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol (2007) 1.46
Defining and investigating social disparities in cancer: critical issues. Cancer Causes Control (2005) 1.46
Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat (2003) 1.44
Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm (2006) 1.42
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
Challenges for biomarkers in cancer detection. Ann N Y Acad Sci (2004) 1.38
Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing--Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morb Mortal Wkly Rep (2004) 1.23
Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine (2006) 1.20
New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines (2007) 1.19
Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health (2005) 1.18
Research challenges for electronic health records. Am J Prev Med (2007) 1.12
Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin (2007) 1.10
Access to care: remembering old lessons. Health Serv Res (2002) 1.04
Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol (2007) 1.00
Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr (2004) 0.98
Putting pharmacogenetics into practice. Nat Biotechnol (2006) 0.97
Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol (2006) 0.97
Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet (2004) 0.93
Decision aids from genetics to treatment of breast cancer: long-term clinical utility or temporary solution? JAMA (2004) 0.92
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care (2004) 0.91
Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A (2005) 0.91
Current impact of gene technology on healthcare. A map of economic assessments. Health Policy (2006) 0.91
Opportunities and barriers in the age of team science: strategies for success. Cancer Causes Control (2006) 0.90
A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynaecol Obstet (2006) 0.89
Building and maintaining an interdisciplinary research team. Alzheimer Dis Assoc Disord (1999) 0.85
Cancer surveillance and information: balancing public health with privacy and confidentiality concerns (United States). Cancer Causes Control (2006) 0.85
An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics (2003) 0.84
Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol (2006) 0.82
Standards for validation of cancer biomarkers. Cancer Biomark (2005) 0.82
Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. Value Health (2006) 0.81
Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn (2006) 0.80
The role of coronary CT angiography (CTA) for patients presenting with acute chest pain. Defining problem-specific, evidence-based indications of a novel imaging modality. Int J Cardiovasc Imaging (2007) 0.79
The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant? Med Decis Making (2003) 0.79
Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia. Oncology (Williston Park) (2006) 0.78
Quality assurance and technology assessment: pieces of a larger puzzle. J Qual Clin Pract (2001) 0.78
The changing physician workforce landscape: implications for physical medicine and rehabilitation. Am J Phys Med Rehabil (2007) 0.77
Standards and controls for genetic testing. Cancer Biomark (2005) 0.77
Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics (2006) 0.77
The future of cancer surveillance. Cancer Causes Control (2006) 0.76
msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA (2001) 0.76
Brain imaging in neonatal clinical trials: in search of a gold standard. J Pediatr (2007) 0.76
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Global health 2035: a world converging within a generation. Lancet (2013) 16.85
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Primary care physicians who treat blacks and whites. N Engl J Med (2004) 12.23
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Letting the genome out of the bottle--will we get our wish? N Engl J Med (2008) 9.10
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med (2011) 8.48
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA (2006) 8.16
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst (2008) 7.85
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol (2006) 7.66
Public expectations for return of results from large-cohort genetic research. Am J Bioeth (2008) 7.63
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol (2009) 6.77
Care patterns in Medicare and their implications for pay for performance. N Engl J Med (2007) 6.74
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst (2002) 6.64
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Using navigators to improve care of underserved patients: current practices and approaches. Cancer (2005) 5.56
Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA (2004) 5.43
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
A navigator for human genome epidemiology. Nat Genet (2008) 5.07
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst (2009) 5.05
Trends and disparities in socioeconomic and behavioural characteristics, life expectancy, and cause-specific mortality of native-born and foreign-born populations in the United States, 1979-2003. Int J Epidemiol (2006) 4.99
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
High rates of adverse drug events in a highly computerized hospital. Arch Intern Med (2005) 4.68
Screening for breast cancer. JAMA (2005) 4.56
Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol (2008) 4.53
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Subjects matter: a survey of public opinions about a large genetic cohort study. Genet Med (2008) 4.52
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol (2005) 4.46
Genomics and drug response. N Engl J Med (2011) 4.35
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist (2013) 4.33
Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health (2009) 4.33
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
How to build and interpret a nomogram for cancer prognosis. J Clin Oncol (2008) 4.24
Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res (2003) 4.22
Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2011) 4.22
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: a systematic review. Am J Prev Med (2004) 4.07
Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA (2009) 4.04
The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med (2003) 4.01
Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med (2006) 4.01
Approaching health disparities from a population perspective: the National Institutes of Health Centers for Population Health and Health Disparities. Am J Public Health (2008) 3.98
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
Public opinion about the importance of privacy in biobank research. Am J Hum Genet (2009) 3.85
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol (2006) 3.83
Health and economic implications of HPV vaccination in the United States. N Engl J Med (2008) 3.81
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Introducing HPV vaccine in developing countries--key challenges and issues. N Engl J Med (2007) 3.77
Can family history be used as a tool for public health and preventive medicine? Genet Med (2002) 3.76
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol (2006) 3.75
Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst (2004) 3.74
National Institutes of Health approaches to dissemination and implementation science: current and future directions. Am J Public Health (2012) 3.72
Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med (2004) 3.64
The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. Am J Obstet Gynecol (2002) 3.63
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol (2007) 3.60
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med (2009) 3.59
Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care (2002) 3.57
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med (2005) 3.55
Delivery of preventive services to older adults by primary care physicians. JAMA (2005) 3.53
Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care (2005) 3.53
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol (2005) 3.38
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29